Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from April 2, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 1, 2026 — +25.1% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$930.00 – $955.00Entry zone — fair-value band

$952.56Published — price the day we called it

$1,085.92Target — the price the thesis aimed for

$1,238.00Peak — highest point inside the window, not a realized return

$1,191.74Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 55 days.

At window close

+25.1%

realized, from the publication price to the last close inside the window

Peak gain

+30%

peak, from the publication price — not a realized return

S&P 500, same window

+14%

SPY over the identical days, dividend-adjusted

Window close

$1,191.74

last close inside the window, ended July 1, 2026

Peak price

$1,238.00

peak on June 29, 2026 — not a realized return

Days to target

The thesis — published April 2, 2026

Predicted growth

+14%

over the measurement window

Target price

$1,085.92

the price the thesis aimed for

Entry zone

$930.00 – $955.00

the fair-value band we waited for

Price at publication

$952.56

published April 2, 2026

Confidence

80%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly looks like a relatively steady growth option for the next few months because a new obesity drug launch on April 6 keeps attention on its leadership in that area and pushes sales estimates higher. Good trial results also back up the wider drug pipeline. Shares have run up, so a calmer rise after a small pullback feels safer than chasing higher prices now.

Primary drivers

April 6 drug launch keeps obesity leadership visible and may lift sales
Positive trial results make the broader drug pipeline more credible
Health-care stock traits can steady returns when markets swing
A pullback into the entry band looks safer than buying after the rally

How it played out

LLY: target reached in 55 days

Lyra published a short-term thesis at $952.56 and expected 14% growth. The thesis pointed to an April 6 obesity drug launch, positive trial results, the steadier traits of health-care stocks, and a pullback into the $930 to $955 entry band.

The shares reached the $1,085.92 target in 55 days. They later peaked at $1,238 on June 29, a 30% gain, and ended the window at $1,191.74. The thesis played out and exceeded its stated target.

What happened during the window

On April 30, Lilly reported first-quarter revenue of $19.8 billion, up 56%, and raised its full-year revenue guidance. On June 7, the company announced additional results from its Foundayo obesity studies in women.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals